RILP and prostate cancer: Lysosomal trafficking is emerging as novel therapeutic target for cancer.35 RILP interacts with Rab7, Rab34 and dynein/dynactin complex to regulate late endosomal/lysosomal trafficking from peripheral region to peri-Golgi region marked by MTOC,18, 19, 36 this event may inhibit the anterograde transport and result in the suppression of invasion of prostate cancer cells.22, 23 Our works demonstrated that RILP suppresses cell proliferation, migration and invasion of breast cancer cells, supporting that RILP may function as tumor suppressor.